Prosecution Insights
Last updated: May 28, 2026
Application No. 17/225,151

Rheological Solid Composition for Use in Shaving

Non-Final OA §DOUBLEPATENT
Filed
Apr 08, 2021
Priority
Apr 10, 2020 — provisional 63/007,972
Examiner
ROBERTS, LEZAH
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Procter & Gamble Company
OA Round
7 (Non-Final)
49%
Grant Probability
Moderate
7-8
OA Rounds
0m
Est. Remaining
85%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
368 granted / 756 resolved
-11.3% vs TC avg
Strong +36% interview lift
Without
With
+36.3%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
62 currently pending
Career history
832
Total Applications
across all art units

Statute-Specific Performance

§101
0.1%
-39.9% vs TC avg
§103
77.8%
+37.8% vs TC avg
§102
3.9%
-36.1% vs TC avg
§112
2.1%
-37.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 756 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments in the Request for Continued Examination, filed June 26, 2025, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims Newly submitted claims 22-23 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: the claims would have been restricted as follows. Election by Original Presentation Restriction to one of the following inventions is required under 35 U.S.C. 121: I. Claims 1, 10-13 and 16, drawn to a rheological solid share care composition, classified in A61K 9/00. II. Claims 17-20, drawn to a process for the manufacture of a rheological solid shave care composition, classified in A61K 2800/00. III. Claims 22-23, drawn to a shave care with an implement, classified in B26B 21/00. The inventions are independent or distinct, each from the other because: Inventions II and I & III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make another and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the product may be made using anhydrous solvents, using a different base or a different salt. Inventions I and III are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because Invention I does require an implement. The subcombination has separate utility such as balm. The examiner has required restriction between combination and subcombination inventions. Where applicant elects a subcombination, and claims thereto are subsequently found allowable, any claim(s) depending from or otherwise requiring all the limitations of the allowable subcombination will be examined for patentability in accordance with 37 CFR 1.104. See MPEP § 821.04(a). Applicant is advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 22-23 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03. To preserve a right to petition, the reply to this action must distinctly and specifically point out supposed errors in the restriction requirement. Otherwise, the election shall be treated as a final election without traverse. Traversal must be timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are subsequently added, applicant must indicate which of the subsequently added claims are readable upon the elected invention. Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103 or pre-AIA 35 U.S.C. 103(a) of the other invention. Obvious-Type Double Patenting (New Rejections) The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 1) Claims 1, 10-13 and 16 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 14-16, 19-39 and 41 of copending Application No. 17/225,146 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims are coextensive insofar as they recite rheological solids comprising a crystallizing agent and suspension agent. The instant claims differ from the copending claims insofar as the instant claims are species claims because they recite a specific combination of crystallizing agents and a specific combination of suspension agents whereas the copending claims recited specific combinations in the independent claims. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. 2) Claims 1, 10-13 and 16 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-7 of U.S. Patent No. 12,138,333. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims are coextensive insofar as they recite rheological solids comprising a crystallizing agent. The instant claims differ from the patented claims insofar as they recite a specific crystallizing agent and do not recite sodium chloride in the independent claim. However the instant claims recite sodium chloride in the dependent claims. The claims are obvious over the patented claims. 3) Claims 1, 10-13 and 16 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 12,138,328. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims are coextensive insofar as they recite rheological solids comprising a crystallizing agent. The instant claims differ from the patented claims insofar as they recite a specific crystallizing agent and do not recite sodium chloride in the independent claim. However the instant claims recite sodium chloride in the dependent claims. The claims are obvious over the patented claims. Conclusion .Claims 1, 10-13 and 16 are rejected. Claims 17-20 and 22-23 are withdrawn. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LEZAH ROBERTS whose telephone number is (571)272-1071. The examiner can normally be reached Monday-Friday 11:00-7:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Frederick Krass can be reached on 571-272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LEZAH ROBERTS/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Show 9 earlier events
Nov 14, 2024
Response Filed
Dec 04, 2024
Non-Final Rejection mailed — §DOUBLEPATENT
Mar 04, 2025
Response Filed
Mar 27, 2025
Final Rejection mailed — §DOUBLEPATENT
Jun 26, 2025
Request for Continued Examination
Jun 30, 2025
Response after Non-Final Action
Jul 16, 2025
Non-Final Rejection mailed — §DOUBLEPATENT
Oct 14, 2025
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594229
Personal Care Compositions and Methods for the Same
5y 2m to grant Granted Apr 07, 2026
Patent 12594241
TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOF
2y 7m to grant Granted Apr 07, 2026
Patent 12582583
ORAL CARE PRODUCT COMPRISING AN ORAL CARE RHEOLOGICAL SOLID COMPOSITION
4y 11m to grant Granted Mar 24, 2026
Patent 12558387
MULTI-VIRUS ANTI-INFECTIVITY AND PRO-IMMUNITY ASSEMBLY
2y 2m to grant Granted Feb 24, 2026
Patent 12551417
STABILIZED STANNOUS COMPOSITIONS
1y 1m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
49%
Grant Probability
85%
With Interview (+36.3%)
4y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 756 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month